Haemophilus influenzae type b Polysaccharide Capsule Antigen (Conjugated) (Hib PRP Conjugate)

The polyribosyl-ribitol-phosphate (PRP) polysaccharide capsule antigen of Haemophilus influenzae type b (Hib) is a key virulence factor that enables the bacterium to evade immune responses. Hib conjugate vaccines are formulated by covalently linking PRP to a carrier protein (e.g., tetanus toxoid, diphtheria toxoid, or Neisseria meningitidis OMP), which converts the T-cell independent response to PRP into a T-cell dependent response, enhancing immunogenicity and memory in infants and young children. Vaccination leads to the production of anti-PRP antibodies, preventing invasive Hib disease.

Other names

Polyribosyl-ribitol-phosphate (PRP) polysaccharideHib capsular polysaccharidePRP-DHbOCPRP-TPRP-OMP

The Hib conjugate vaccine elicits a T-cell dependent immune response, leading to the production of antibodies against the PRP capsular polysaccharide. These antibodies neutralize the Hib bacteria, preventing them from causing invasive disease.